Experimental cocktail aims to battle resistant blood cancers
NCT ID NCT06207123
Summary
This early-stage study is testing whether an experimental drug called LP-118 can be safely combined with an approved leukemia drug, ponatinib, and standard chemotherapy. The goal is to find the safest and most effective dose for patients whose T-cell acute lymphoblastic leukemia or lymphoma has come back or isn't responding to current treatments. Researchers will closely monitor side effects and see if the combination helps put the cancer into remission.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ACUTE LEUKEMIA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
University of Chicago Medicine Comprehensive Cancer Center
RECRUITINGChicago, Illinois, 60615, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
University of Rochester Medical Center, Wilmot Cancer Center
RECRUITINGRochester, New York, 14642, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.